Yes, of course.
I can give a great Hamilton example. One of the reasons that a lot of start-ups in the radiopharmaceutical industry come to the Hamilton area is our expertise. Right now we are hosting a company called AtomVie, but also at our innovation park we have Fusion Pharmaceuticals. That is a spin-out that was started by a McMaster professor. John Valliant started the Centre for Probe Development and Commercialization—I actually worked there for a period of time as the director of discovery—which spun out that branch to Fusion Pharmaceuticals. They were acquired by AstraZeneca for $2.4 billion.
The barrier to entry into nuclear can be high because of the safety components and the regulatory components, but one thing we do really well is help lower that barrier of entry. We help them to be able to come in and work quickly to advance those products into clinical trials.
